Jiangsu Hengrui Medicine's triple-combination diabetes drug gets market approval

Jiangsu Hengrui Medicine Co., through its subsidiary Shandong Shengdi Pharmaceutical Co., has received approval from the National Medical Products Administration for its Henggli Jiping Ruigli Jiting Metformin Sustained-Release Tablets (I) and (II) (HR20031). This drug is China's first self-developed oral triple-combination fixed-dose compound preparation for lowering blood sugar.

The approved specifications are 5/50/750mg and 10/100/1000mg, classified as chemical drug class 2.3. The drug is indicated for adults with type 2 diabetes whose blood glucose is inadequately controlled with metformin, in conjunction with diet and exercise.

This new medication, HR20031, combines prolinate hengliliptin, rigliptin phosphate, and metformin hydrochloride to provide a triple-mechanism approach to blood glucose reduction. It aims to simplify treatment regimens and improve patient adherence for the 148 million people with diabetes in China. Currently, there are no other similar triple-combination products approved in China.

The total research and development investment for the HR20031 project has reached approximately CNY 18,924m. The company emphasizes strict quality control in all stages of development, manufacturing, and sales, while cautioning investors about potential risks associated with pharmaceutical products.